Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

Study on Investigational Medication for Newly Diagnosed Immune Thrombocytopenia

Recruiting
1 years - 17 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to determine if Eltrombopag is as effective of a treatment for patients with newly diagnosed Immune Thrombocytopenia (ITP) when compared to standard treatment.

Detailed description of study

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Immune Thrombocytopenia
  • Age: 1 years - 17 years
  • Gender: All

Inclusion Criteria
Newly diagnosed ITP (Requires pharmacologic treatment from the perspective of the treating clinician.

This study investigates the effectiveness of an investigational medication for patients with newly diagnosed Immune Thrombocytopenia (ITP). ITP is a condition where the immune system attacks and destroys platelets, which are cells in the blood that help with clotting. This study aims to compare the investigational medication with the standard treatment to see if it is as effective.

Participants in this study will receive either the investigational medication or the standard treatment as part of their care. The study will monitor how well the treatments work and their effects on the participants' platelet counts.

  • Who can participate: Individuals who have been diagnosed with ITP within the last 3 months and require treatment according to their doctor can participate.
  • Study details: Participants will receive either the investigational medication or the standard treatment. The study will compare the effects of these treatments on platelet counts.
Updated on 10 Jul 2026. Study ID: 1905858882 (PHO-BAYLOR-ICON3)

Pre-Screener

Check your eligibility

  • Take up this questionnaire to help us determine if you have symptoms that are common to this clinical study.
  • If you have the common symptoms, you may be eligible to take part in the study.

Preview complete

The prescreener preview is complete. You may now close the preview.

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team